Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Anal Cancer
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
Squamous cell carcinoma of the anus is still a rare disease but its incidence increases mostly due to its association with human papillomavirus (HPV).
- Trial name
- KANALRAD (NCT06207981)
- Testing
- induction chemotherapy (mDCF), Concomitant chemotherapy (Capecitabin + Mitomycin-C), radiotherapy
- Where
- 114 sites in France, Reunion
- Volunteers
- 310 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Rectal Cancer
"Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
Among patients treated for locally advanced rectal cancer with neo-adjuvant radio-chemotherapy, about 15% will have complete clinical response in terms of no visible tumor or ulcerations on the site of the primary tumor, or…
- Trial name
- NORWAIT (NCT03402477)
- Where
- 7 sites in Norway
- Volunteers
- 86 people
- Sponsor
- Helse Stavanger HF
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Rectal Cancer, Non-Small Cell Lung Cancer
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer…
- Trial name
- NCT06337552
- Testing
- FEED-FF, Standard of Care (SUC)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
COPERNIC is an international, multicentre, single-arm study. Chemo-refractory mCRC subjects who meet all eligibility criteria will be treated with standard systemic chemotherapy (the decision about the treatment regimen being…
- Conditions
- Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Candidate for Third-line or Subsequent Lines of Therapy
- Trial name
- COPERNIC (NCT05487248)
- Testing
- Blood Sample Collection
- Where
- 12 sites in Belgium, France
- Volunteers
- 103 people
- Sponsor
- Jules Bordet Institute
Advanced Rectal Cancer, Distal Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis
Though surgical resection remains the primary choice for advanced rectal cancer, about 80% are considered unresectable due to the number, size, or location of metastases.
- Trial name
- Miracle-2 (NCT05359406)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- LI XIN-XIANG
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Locally Advanced Rectal Cancer
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
- Trial name
- NCT03238885
- Testing
- pelvic MR examination
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Sun Ying-Shi
Colorectal Cancer
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- Trial name
- NCT04468607
- Testing
- BLYG8824A
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth…
- Trial name
- NCT00026299
- Testing
- ZD1839, oxaliplatin
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
Rectal Cancer
Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells
During the course of tumor growth and possibly by manipulation during the surgical procedure, cells from rectal tumors may be shed into the peritoneal cavity.
- Trial name
- LARC-EX (NCT02113384)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 231 people
- Sponsor
- Oslo University Hospital
Colorectal Neoplasms
Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer
The purpose of this study is to determine the efficacy and safety of Andrographolides combined with Capecitabine in treatment of elderly patients with locally advanced or recurrent or metastasis inoperable colorectal cancer
- Trial name
- AGCRC-013 (NCT01993472)
- Testing
- Andrographolides, Capecitabine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Gu Yanhong
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Rectal Cancer
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the…
- Trial name
- NCT02933944
- Testing
- TG02-treatment, Pembrolizumab
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 6 people
- Sponsor
- Targovax ASA
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
- Trial name
- NCT06234007
- Testing
- Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Preoperative radiotherapy combined with 5-fluorouracil/capecitabine is currently the standard treatment for locally advanced rectal cancer.
- Trial name
- ESTIMATE (NCT06239870)
- Testing
- Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yunnan Cancer Hospital
Colorectal Cancer
Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.
All patients with locally advanced colorectal cancer after radical surgical intervention who have not previously received systemic antitumor treatment will be randomized into two groups receiving fluoropyrimidines in mono-regimen…
- Trial name
- AHTCRR-1 (NCT06888843)
- Testing
- Capecitabine, Oxaliplatin
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
Locally Advanced Cancer in the Anal Region
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region To evaluate acute toxicity…
- Trial name
- NOAC8 (NCT01621217)
- Testing
- Cetuximab, Mitomycin C, 5-Fluoruracil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 21 people
- Sponsor
- Lund University Hospital